Estimated cumulative incidence rate and radiologic presentation of P jirovecii in a CLL patient treated with ibrutinib. (A) The estimated cumulative incidence of PCP in CLL is 4.5% at 1 year on ibrutinib, and 5.6% at 2 years and thereafter. The cumulative incidence of PCP was estimated by considering deaths or early discontinuation of ibrutinib without PCP as competing risk events; otherwise, patients on ibrutinib treatment were censored at the last follow up if no PCP was observed.¹¹  (B-E) Chest CT images of 2 patients are shown who were diagnosed with and treated for PCP while on ibrutinib. The first patient presented with multifocal ground-glass opacificies (B), which significantly improved after treatment of PCP (C). The second patient presented with unilateral nodular infiltrates (D), which resolved after treatment (E).